BAKER BROS. ADVISORS LP Q4 2022 Filing
Filed February 14, 2023
Portfolio Value
$16.7T
Holdings
113
Report Date
Q4 2022
Filing Type
13F-HR
All Holdings (113 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 101 | AGLEUSDAeglea BioTherapeutics, Inc. | 3,410,106 | $1.5B | 0.01% | |
| 102 | —TCR2 Therapeutics Inc. | 753,064 | $752.0M | 0.00% | |
| 103 | TARAProtara Therapeutics, Inc. | 199,671 | $535.0M | 0.00% | |
| 104 | —Genetron Holdings Limited | 455,306 | $509.0M | 0.00% | |
| 105 | KZRKezar Life Sciences, Inc. | 61,946 | $436.0M | 0.00% | |
| 106 | IM8NInsmed Incorporated | 19,950 | $398.0M | 0.00% | |
| 107 | FHTXFoghorn Therapeutics Inc. | 45,027 | $287.0M | 0.00% | |
| 108 | SERASera Prognostics, Inc. | 201,562 | $253.0M | 0.00% | |
| 109 | LPTXEURLeap Therapeutics, Inc. | 559,705 | $251.0M | 0.00% | |
| 110 | —Vincerx Pharma, Inc. | 241,379 | $246.0M | 0.00% | |
| 111 | —Bellicum Pharmaceuticals, Inc. | 249,123 | $179.0M | 0.00% | |
| 112 | SRZNWSurrozen, Inc. | 833,333 | $45.0M | 0.00% | |
| 113 | ATYRaTyr Pharma, Inc. | 8,565 | $18.0M | 0.00% |
PreviousPage 2 of 2